CXCR2 and prostate carcinoma: We cocultured PC3 prostate cancer cells with PBMCs isolated from the spleens of NSG mice to evaluate changes in CXCR1 and CD47 expression in tumour cells and alterations in immune cell infiltration within the tumour microenvironment under conditions involving the inhibition of two key metabolic enzymes (PDC-E2 and FAS) or blockade of the CXCR2 signalling pathway (Supplemental Fig. 5 A).